Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual)

v3.5.0.2
Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Significant Accounting Policies [Line Items]          
Reduction In Net Loss Attributable To Common Stock Holders     $ 2,358    
Medical Device [Member]          
Significant Accounting Policies [Line Items]          
Reduction In Net Loss Attributable To Common Stock Holders     2,358    
Deferred Revenue, Revenue Recognized         $ 6,517
Cost of Revenue         $ 4,159
Product Liability Accrual, Component Amount $ 212   212    
Customer Advances and Deposits, Current, Total $ 911   $ 911    
Minimum [Member] | Medical Device [Member]          
Significant Accounting Policies [Line Items]          
Revenue Maintenance Contractual Agreement Term     1 year    
Maximum [Member] | Medical Device [Member]          
Significant Accounting Policies [Line Items]          
Revenue Maintenance Contractual Agreement Term     4 years    
Accounts Receivable [Member]          
Significant Accounting Policies [Line Items]          
Concentration Risk, Percentage     13.00%    
Sales Revenue, Net [Member]          
Significant Accounting Policies [Line Items]          
Concentration Risk, Percentage 15.00%   10.00%    
Customer One [Member] | Accounts Receivable [Member]          
Significant Accounting Policies [Line Items]          
Concentration Risk, Percentage     10.00%   10.00%
Customer One [Member] | Sales Revenue, Net [Member]          
Significant Accounting Policies [Line Items]          
Concentration Risk, Percentage 10.00% 48.00%   33.00%